Received Mar 28, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | — | — |
agent called on behalf of a consumer friend who reported via text that she experienced injection site redness and swelling after receiving CAPVAXIVE. The CAPVAXIVE was administered on 3/15/25 at a pharmacy. The consumer reported ha; headache; vaccination site swelling; fever; body chills; body aches; This spontaneous report was received from the patient's friend and refers to a female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions included Celiac disease, and Asthma. Concomitant therapies were not reported. On 15-Mar-2025, the patient was vaccinated with a dose of Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) (strength, dose, dose number, route, anatomical location, lot # and expiration date were not reported) for prophylaxis. On unspecified date in March 2025 at a pharmacy (also reported as: After receiving CAPVAXIVE), the patient experienced injection site redness and swelling , also experienced fever, body chills, body aches and headaches. It was mentioned that as of 17-MAR-2025, the patient reported feeling better, however the outcome of all adverse events was reported as recovering. The causal relationship between all adverse events and Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE) was not provided.
Asthma; Celiac disease